Vir Biotechnology, Inc. VIR
9.96 USD -2.16 (-17.82%)
Regular-session close
9.92 -0.04 -0.40%
Pre-market · Nov 16, 5:35 AM ET
9.71 Day range 10.70
5.32 52-week range 14.38
- YTD
- +65.17%
- 1 year
- +82.08%
News
benzinga.com Why Is Vir Biotechnology Stock Falling Friday? Vir Biotechnology (VIR) stock drops 16% premarket after pricing a $150M public offering at $10/share. See key technical levels to watch.
businesswire.com Vir Biotechnology Announces Pricing of Public Offering of Common Stock SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and…
businesswire.com Vir Biotechnology Announces Proposed Public Offering SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and…benzinga.com Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28 Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $25 to $28.
benzinga.com Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25 Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $22 to $25.
marketbeat.com Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48 Vir Biotechnology NASDAQ: VIR said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated…
seekingalpha.com Vir Biotechnology: Fairly Valued After Phase 3 Success? Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. VIR's Hepatitis Delta therapy achieved 44% primary endpoint success and 79% undetectable…
seekingalpha.com Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript Vir Biotechnology, Inc. ( VIR ) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data November 9, 2026 8:30 AM EST Company Participants Kiki Patel - Head of Investor Relations Marianne De…
investors.com Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.benzinga.com HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $22 price target.
zacks.com Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know The mean of analysts' price targets for Vir Biotechnology (VIR) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
benzinga.com Vir Biotech Highlights Significant Viral Suppression in Advanced Liver Disease Study Vir Biotechnology reported positive Phase 3 ECLIPSE 1 data for its chronic hepatitis delta treatment ahead of planned 2027 FDA filings.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
benzinga.com Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Greenfire shares surged 25% after Strathcona announced a C$2.7B-C$2.9B acquisition; several small-cap stocks posted sharp premarket gains and losses.benzinga.com Reported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment100% of patients achieved virologic response at Week 24 with 79% of patients reaching…
benzinga.com Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20 Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $18 to $20.
benzinga.com Vir Biotechnology Q3 2026 Earnings Call Transcript Vir Biotechnology (NASDAQ:VIR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
